ZYME - Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

2024-02-06 10:04:54 ET

Summary

• Zymeworks' share price is moving higher lately, led by an overall recovery of biotech stocks, and possibly by increased investor interest in the company’s emerging antibody-drug conjugate platform.
• The topline results from the phase 3 trial of zanidatamab in patients with GEA are expected in late 2024, and are the most important event for the stock this year.
• Zanidatamab has the potential to become an important treatment option for GEA and patients, and potentially other HER2-positive cancers, and could generate significant royalties for Zymeworks if approved.
• The bispecific and multispecific antibody pipeline and the ADC pipeline will become increasingly important in 2025 and beyond.

Shares of Zymeworks ( ZYME ) are moving higher lately, led by an overall recovery of biotech stocks, and, perhaps, by increased investor interest in the company’s emerging antibody-drug conjugate (‘ADC’) platform.

Zymeworks and its partner Jazz Pharmaceuticals ( JAZZ ) also continued to make progress with zanidatamab. In my previous article on Zymeworks, I said the deal with Jazz provides a new life for the company and a strong cash balance to expand its pipeline....

For further details see: